Aligos Therapeutics Inc
ALGS
Company Profile
Business description
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
Contact
One Corporate Drive
2nd Floor
South San FranciscoCA94080
USAT: +1 800 466-6059
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
82
Stocks News & Analysis
stocks
Nvidia earns upgrade as AI buildouts accelerate
Demand for AI infrastructure shows no signs of slowing.
stocks
Weekly earnings wrap: FMG, WDS, COL and more
A closer look at the final major results from August reporting season.
stocks
Chart of the Week: Are US mega-cap stocks undervalued?
Opportunities emerge across US equities.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,243.20 | 84.80 | -0.91% |
| CAC 40 | 8,319.87 | 142.52 | -1.68% |
| DAX 40 | 26,367.24 | 81.28 | 0.31% |
| Dow JONES (US) | 53,618.51 | 154.63 | 0.29% |
| FTSE 100 | 10,792.54 | 85.58 | -0.79% |
| HKSE | 25,565.74 | 87.23 | -0.34% |
| NASDAQ | 26,481.05 | 350.85 | 1.34% |
| Nikkei 225 | 66,131.98 | 130.18 | -0.20% |
| NZX 50 Index | 13,880.05 | 133.16 | -0.95% |
| S&P 500 | 7,724.18 | 48.48 | 0.63% |
| S&P/ASX 200 | 9,038.20 | 78.20 | -0.86% |
| SSE Composite Index | 3,956.57 | 44.05 | 1.13% |